This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Drug Enforcement Administration (DEA), Department of Justice.
Notice of proposed rulemaking; extension of comment period.
The Drug Enforcement Administration (DEA) is extending the comment period and time to request a hearing on the Federal Register Notice of proposed rulemaking entitled “Schedules of Controlled Substances: Placement of Embutramide into Schedule III” published on July 29, 2005 (70 FR 43809).
The period for public comment that was to close on August 29, 2005, will be extended to September 28, 2005.
To ensure proper handling of comments, please reference “Docket No. DEA-269P” on all written and electronic correspondence. Written comments being sent via regular mail should be sent to the Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL. Written comments sent via express mail should be sent to the Deputy Administrator, Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, VA 22301. Comments may be directly sent to DEA electronically by sending an electronic message to firstname.lastname@example.org. Comments may also be sent electronically through http://www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this document is also available at the http://www.regulations.gov Web site. DEA will accept electronic comments containing MS Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.End Further Info End Preamble Start Supplemental Information
DEA published a Notice of Proposed Rulemaking (70 FR 43809) proposing the placement of embutramide into Schedule III of the Controlled Substances Act (CSA). The proposed scheduling action is based on a scientific and medical evaluation and recommendation by the Department of Health and Human Services and an evaluation of this and other information by DEA. On August 22, 2005, DEA received a request for an extension of the period in which to comment and request a hearing. The requestor indicated that the additional time is necessary to review the scientific articles and other information cited by DEA in support of its scheduling proposal. Upon consideration of this request, a thirty day extension of the time to comment and request a hearing is granted. This allows sufficient time for interested persons to evaluate and consider all relevant information and respond accordingly. Therefore, the comment period and time to request a hearing is extended to September 28, 2005. Comments must be received by the DEA on or before this date.Start Signature
Dated: August 24, 2005.
Michele M. Leonhart,
[FR Doc. 05-17163 Filed 8-26-05; 8:45 am]
BILLING CODE 4410-09-P